On March 26, 2024, China Resources Shuanghe Pharmaceutical Co., Ltd. showcased a portfolio of flagship over-the-counter (OTC) and prescription products—including Pai’anning® Zao Ren An Shen Granules (a traditional Chinese medicine formulation indicated for insomnia and restlessness), Yuting® and Jinyuting® levonorgestrel emergency contraceptive tablets, and Qingli® dehydrocholic acid lozenges—at the 2026 Xiding Health Industry Conference, one of China’s largest retail pharmacy trade fairs. The event drew strong interest from national pharmacy chain buyers, with Yuting® and Jinyuting® officially recognized as “Top-Selling Products in the Chinese Retail Pharmacy Market (2025–2026)” by industry analysts.
In a strategic expansion into ophthalmology, China Resources Zizhu—Shuanghe’s specialty pharmaceutical subsidiary—launched “Jiankang,” a new dedicated ophthalmic brand. Positioned as “a trusted partner for physicians and the preferred choice for patients managing common eye conditions,” Jiankang signals the company’s formal entry into the rapidly growing segment of community-based eye care. At the conference, the Jiankang brand pavilion generated significant engagement, with multiple regional pharmacy chains expressing intent to co-develop clinical education programs and integrated patient support services.
During a high-level roundtable discussion, Mr. Youlong Zhai, Deputy General Manager of Marketing at Shuanghe’s General Medicines Division, outlined the company’s evolving commercial model: shifting from transactional product distribution toward comprehensive health management. Central to this transformation is an integrated ecosystem anchored by three pillars—evidence-informed prevention, targeted pharmacotherapy, and structured rehabilitation—and supported by six disease-specific Health Management Centers, AI-enabled digital tools for chronic disease monitoring (including hypertension, diabetes, and dyslipidemia), and a closed-loop outpatient support system that extends care beyond the clinic setting. This framework is designed to empower pharmacy chains to evolve from “medication dispensers” into “community health stewards”—enhancing patient retention, improving practice-level profitability, and strengthening brand equity.
Concurrently, Shuanghe convened its National Provincial Strategy Forum, bringing together regional marketing leads to align on implementation priorities—including Health Management Center rollout timelines, frontline staff training protocols, and collaborative KOL engagement strategies—to accelerate market execution ahead of the 2026 commercial cycle.
Looking ahead to China’s 15th Five-Year Plan (2026–2030), Shuanghe reaffirmed its commitment to innovation-driven growth, patient-centric development, and ecosystem collaboration. By deepening therapeutic expertise across core franchises—including women’s health, neurology, respiratory care, and now ophthalmology—and coupling robust product portfolios with scalable channel enablement, the company aims to advance sustainable, value-based healthcare delivery and contribute meaningfully to the national Healthy China 2030 initiative.